Sodium Chloride Solution 0.9% — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

5 Recruiting

6 Completed trials

11 Sponsors

12 Countries

Phase III

Phase II

Phase I/II

Phase III: 5 Phase II/III: 1 Phase II: 3 Phase I/II: 2 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

1 serious breach 3 temporary halts 1 unexpected event across 3 trials

View oversight register →

Indications tested

Distributive shock 1 Respiratory tract infection 1 Netherton's syndrome 1 Methylmalonic aciduria 1 Sternotomy 1 Lyme disease 1 Skin dystrophy 1

Sponsors using this IMP

Moderna Inc. 3 Centre Hospitalier Universitaire De Bordeaux 1 Centre Hospitalier Universitaire De Nantes 1 Clinica Universidad De Navarra 1 Daiichi Sankyo Inc. 1 Instituto De Investigacion Marques De Valdecilla 1 Les Hopitaux Universitaires De Strasbourg 1 Paion Pharma GmbH 1 Pfizer Inc. 1 TargED Biopharmaceuticals B.V. 1 University Medical Center Utrecht 1

All trials

13 total

Botulinum toxin injection after sternotomies to improve scar aspect and impact Pending

2025-521290-14-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
A study testing the medicine angiotensin II in patients of 0–17 years with a life-threateningly low blood pressure Pending

2025-523750-14-00 Phase III 4 countries Paion Pharma GmbH
Methotrexate treatment in hand osteoarthritis refractory to usual treatments Recruiting

2022-502362-24-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting

2025-522455-26-00 Phase I/II 3 countries TargED Biopharmaceuticals B.V.
Evaluation of the efficacy of treatment with autovaccines vs antibiotic treatment in subjects with hip or knee prosthesis infections. Recruiting

2024-520226-10-00 Phase III 1 country Instituto De Investigacion Marques De Valdecilla
Novel treatment with botulinum toxin for erectile dysfunction unresponsive to conventional treatment Recruiting

2024-514518-10-00 Phase II 1 country Clinica Universidad De Navarra
Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting

2022-501997-20-00 Phase I (FiH) 3 countries Moderna Inc.
Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care Ended

2022-501707-27-01 Phase II/III 6 countries University Medical Center Utrecht
A study to investigate the reactogenicity, safety, and immunogenicity of mRNA-1345 in pregnant women, and safety and immunogenicity in their… Ended

2023-505359-37-00 Phase II 1 country Moderna Inc.
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended

2022-502022-41-00 Phase I (Other) 3 countries Moderna Inc.
An early-stage clinical study of a potential new medicine for patients with Netherton Syndrome Ended

2022-502853-32-00 Phase I/II 1 country Daiichi Sankyo Inc.
Phase 3, Placebo-Controlled, Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Trial of a 6-Valent OspA-Based Lyme Disease… Ended

2023-509105-72-00 Phase III 5 countries Pfizer Inc.
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended

2024-517309-95-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg

Showing 1–13 of 13 trials

← All drugs A–Z